Search
Now showing items 1-7 of 7
Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges
(Baishideng Publishing Group, 2018-10-07)
Abstract
Latin America, a region with a population greater than 600000000 individuals, is well known due to its wide geographic, socio-cultural and economic heterogeneity. Access to health care remains as the main barrier ...
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
(Wiley, 2019-01-13)
Abstract
Background & Aims: Data from Europe and North America have been published re‐
garding the risk of developing hepatocellular carcinoma (HCC) after treatment with
direct antiviral agents (DAA). We proposed to ...
Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission
(Elsevier, 2021-03)
Abstract
Introduction & objectives: The independent effect of liver biochemistries as a prognostic factor in patients with COVID-19 has not been completely addressed. We aimed to evaluate the prognostic value of abnormal ...
Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma
(Elsevier, 2020-10)
Abstract
The A.A.E.E.H has developed this guideline for the best care of patients with hepatocellular carcinoma (HCC) from Argentina. It was done from May 2018 to March 2020. Specific clinical research questions were ...
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection
(Springer, 2021-11)
Abstract
Introduction and objectives: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized ...
Reply
(Elsevier, 2021-03)
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.
(Elsevier, 2020-10)
Abstract
Background & aims: Little is known about how a sustained virologic response (SVR) to treatment of hepatitis C virus infection with direct-acting antivirals (DAAs) affects patient mortality and development of new ...